E-Therapeutics PLC
LSE:ETX

Watchlist Manager
E-Therapeutics PLC Logo
E-Therapeutics PLC
LSE:ETX
Watchlist
Price: 9 GBX -6.74% Market Closed
Market Cap: 52.6m GBX

E-Therapeutics PLC
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

E-Therapeutics PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
E-Therapeutics PLC
LSE:ETX
Revenue
ÂŁ475k
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Revenue
$51.1m
CAGR 3-Years
166%
CAGR 5-Years
99%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Revenue
ÂŁ310.2m
CAGR 3-Years
127%
CAGR 5-Years
65%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Revenue
ÂŁ672.8m
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
5%
Oxford BioMedica PLC
LSE:OXB
Revenue
ÂŁ151.2m
CAGR 3-Years
6%
CAGR 5-Years
18%
CAGR 10-Years
28%
No Stocks Found

E-Therapeutics PLC
Glance View

Market Cap
52.4m GBX
Industry
Biotechnology

e-Therapeutics Plc is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. The company is headquartered in Witney, Oxfordshire and currently employs 18 full-time employees. The company went IPO on 2007-11-28. The firm's platform is a combination of databases and a suite of computational tools that employ network analysis, data mining, machine learning, artificial intelligence (Al) and optimization. Its in silico platform serves as a laboratory, which enables it to computationally test potential therapeutic interventions. Its network-driven drug discovery (NDD) technology performs computational phenotypic screens to identify efficacious drugs. Its genome-associated interactions networks (GAINs) technology interprets genomic data in the context of the biological networks, in which the genes function. Its ribonucleic acid (RNA) Interference, (RNAi) platform is in development to complement its computational toolset. The firm identifies new therapeutic approaches to modulate a specific mechanism involved in Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic indications through Galapagos NV (Galapagos).

ETX Intrinsic Value
Not Available

See Also

What is E-Therapeutics PLC's Revenue?
Revenue
475k GBP

Based on the financial report for Jan 31, 2023, E-Therapeutics PLC's Revenue amounts to 475k GBP.

What is E-Therapeutics PLC's Revenue growth rate?
Revenue CAGR 3Y
1%

Over the last year, the Revenue growth was 0%. The average annual Revenue growth rates for E-Therapeutics PLC have been 1% over the past three years .

Back to Top